Navigation Links
Drugs in the pipeline: new therapies that could change treatment strategies
Date:4/15/2008

y to work, you need blood vessels, Jain said. However, the current study adds evidence to a concept called normalization whereby restoring order to blood vessels inside a tumor opens up a window of opportunity for treatment.

Blood vessel normalization allows the vessels that remain to perform more efficiently. With a drug like bevacizumab, some of the tumor vasculature is pruned away immediately, but the vessels that remain become less abnormal, Jain said. These normalized vessels make the surviving cancer cells more vulnerable to the treatments that can now be delivered more efficiently. Cancer therapies in this environment should be maximally effective.

In the current study, researchers enrolled 24 patients with late-stage rectal cancer. All patients completed four cycles of therapy including bevacizumab, additional standard chemotherapy, radiation and surgery.

At four years, local control, or the absence of cancer spread beyond the original tumor site, was observed in 100 percent of patients and disease-free survival in 88 percent.

Of the 24 patients treated, five had no residual cancer. Of the 19 patients with residual disease, 12 displayed severe disease. Downstaging of the tumor was observed in 12 out of 22 observable tumors.

We had shown in previous mouse studies that normalizing blood vessels would decrease tumor activity, but the question with mouse studies is whether it will work in humans, Jain said. This is the first study to confirm the idea of the effect of normalization in patients.


Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity Fc?RIIIa patients with previously-treated follicular lymphoma: LB-70

A second generation, highly targeted monoclonal antibody appears to provide benefit for some patients with follicular lymphoma for whom other treatments have failed, according to results of a phase I c
'/>"/>

Contact: Staci Vernick Goldberg
Staci.goldberg@aacr.org
267-646-0616
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , ... August 03, 2015 , ... ... agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions ... health care costs. , Annually, more than 8.6 million adverse drug events ...
(Date:8/3/2015)... FL (PRWEB) , ... August ... ... most-visited bodybuilding and fitness site and the largest online retailer of nutritional ... Awards. BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. ... lifecycle management solution, as well as announced the date of its next major ... ease of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical ... on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New ... may be accessed via the investor relations section of the Company’s website. , About ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration ... is similar to deoxycholic acid, which occurs naturally in the body and helps absorb ... treat this area of the body. These are invasive procedures and very expensive for ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Exposure to environmental levels of the industrial chemical bisphenol A, ... long-lasting harm to testicular function, according to a new study ... The Endocrine Society,s 92nd Annual Meeting in San Diego. ... after exposure to BPA levels that are lower than what ...
... revelation that the chair of the board of Canada,s ... until April 2010 sends an unfortunate message to the ... states an editorial http://www.cmaj.ca/cgi/doi/10.1503/cmaj.100850 in CMAJ ( ... no place for the tobacco industry on the development ...
... , ... rank search results higher when there is promoter activity behind the website. , ... (PRWEB) June 21, 2010 -- The Active ... called Active Search Results Page Ranking Technology (ASR Ranking). , , ,ASR Ranking allows ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... performance for the year ending March 31, 2010 in spite of the economic turmoil’s impact ... the second half of 2010 compared with the same period last year. , ... Auckland, New Zealand (Vocus) June 21, 2010 ...
... The ... 33 times greater than that reported for our accredited ambulatory surgery centers. , ... (PRWEB) June 18, 2010 ... Michael Jhung et al (JAMA 2010;303(22):2273 - 2279) correctly places emphasis on the importance ...
Cached Medicine News:Health News:Early-life exposure to BPA may affect testis function in adulthood 2Health News:CMAJ calls for resignation of IDRC chair Barbara McDougall 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 3Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 4Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 5Health News:Infection Rate in Accredited Ambulatory Facilities is Lower than in Hospitals 2
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4
... statins for only five weeks at,400 mg/week lowered ... with similarly favorable effects on other,atherogenic lipids, NEW ... Isis Pharmaceuticals, Inc. announced new,results from its Phase ... presented today at the of Cardiology,Annual Scientific Session ...
... Only Illinois Site in Trial , CHICAGO, March ... adult stem cell therapy, Provacel™,experienced a lower number ... significant improvements in heart, lung and,global function compared ... Phase I study data presented at the American ...
Cached Medicine Technology:Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 2Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: